Abstract
Which management strategies are available for ascites in patients with malignancy? Malignant ascites provide easy access to tumor material in the form of cell-free DNA. Ascites fluid and FFPE tissue samples were obtained from three patients with intrahepatic cholangiocarcinoma, ovarian clear cell carcinoma and mucinous adenocarcinoma of the cecum, respectively. cfDNA and DNA/RNA from FFPE were isolated, followed by NGS analysis. NGS analysis of ascitic fluid identified a CHEK2 mutation in the patient with intrahepatic cholangiocarcinoma. In the corresponding FFPE sample from the same patient, sequencing revealed pathogenic mutation in IDH1 gene. On the other hand, analysis of the ascitic fluid from the patient with ovarian clear cell carcinoma detected an ERBB2 gene amplification, a major biomarker for sensitivity to trastuzumab deruxtecan and three other pathogenic mutations in PIK3CA, CTNNB1, RAF1 genes. The molecular profiles of the ascitic fluid and FFPE tissue showed considerable differences. PIK3CA mutation was concordant between the two samples. Additionally, pathogenic mutations were identified in ARID1B, ATR, PALB2 as well as variants of uncertain significance in the FFPE sample. In the third patient, EGFR and TP53 mutations were detected in the FFPE sample, while KRAS, TP53, and GNAS mutations were identified in ascites. Ascites enable repeated analysis and sampling, facilitating targeted treatment and potentially improving patient management in selected cases.